Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor (Q42963582)

11 November 2017

title

Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor (English)

1 reference

11 November 2017

1 reference

Wei Gu

1 reference

11 November 2017

Katherine A Winters

1 reference

11 November 2017

Alykhan S Motani

1 reference

11 November 2017

Renée Komorowski

1 reference

11 November 2017

Ying Zhang

1 reference

11 November 2017

Qingxiang Liu

1 reference

11 November 2017

Xiaosu Wu

1 reference

11 November 2017

Ingrid C Rulifson

1 reference

11 November 2017

Glenn Sivits

1 reference

11 November 2017

Melissa Graham

1 reference

11 November 2017

Hai Yan

1 reference

11 November 2017

Paul Wang

1 reference

11 November 2017

Steve Moore

1 reference

11 November 2017

Tina Meng

1 reference

11 November 2017

Richard A Lindberg

1 reference

11 November 2017

Murielle M Véniant

1 reference

11 November 2017

publication date

20 July 2010

1 reference

American Journal of Physiology - Endocrinology and Metabolism

11 November 2017

published in

1 reference

11 November 2017

volume

299

1 reference

11 November 2017

1 reference

11 November 2017

page(s)

E624-32

1 reference

Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor

11 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00102.2010

GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00102.2010

The biology of incretin hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00102.2010

Minireview: the glucagon-like peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00102.2010

The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00102.2010

Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00102.2010

Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00102.2010

Glucagon and regulation of glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00102.2010

Pharmacokinetic and pharmacodynamic modeling of a monoclonal antibody antagonist of glucagon receptor in male ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00102.2010

Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00102.2010

Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00102.2010

Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00102.2010

Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00102.2010

Glycemic control in mice with targeted disruption of the glucagon receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00102.2010

Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00102.2010

Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00102.2010

Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00102.2010

Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00102.2010

Localization of glucagon-like peptide (GLP) immunoreactants in human gut and pancreas using light and electron microscopic immunocytochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00102.2010

Extrapancreatic effects of GIP and GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00102.2010

Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00102.2010

Exenatide sensitizes insulin-mediated whole-body glucose disposal and promotes uptake of exogenous glucose by the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00102.2010

10.1152/AJPENDO.00102.2010

21 January 2018

Identifiers

DOI

1 reference

11 November 2017

1 reference